This interview with a US-based KOL provides insights into current prescribing habits for hemophilia A, hemophilia B, and von Willebrand disease, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for hemophilia A and B. Key assets highlighted include Hemlibra, Altuviiio, concizumab, marstacimab, fitusiran, Vonvendi, Wilate, NovoSeven, SevenFact, FEIBA NF, Alprolix, Idelvion, Rebinyn, Alphanate, Rixubis, BeneFIX, Ixinity, Roctavian, Hemgenix, Beqvez, giroctocogene fitelparvovec, SerpinPC, and Mim8. 

This interview was conducted on 14 May 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.